@article{10.1371/journal.pntd.0001376, doi = {10.1371/journal.pntd.0001376}, author = {Martínez-Sernández, Victoria AND Muiño, Laura AND Perteguer, María Jesús AND Gárate, Teresa AND Mezo, Mercedes AND González-Warleta, Marta AND Muro, Antonio AND Correia da Costa, José Manuel AND Romarís, Fernanda AND Ubeira, Florencio M.}, journal = {PLOS Neglected Tropical Diseases}, publisher = {Public Library of Science}, title = {Development and Evaluation of a New Lateral Flow Immunoassay for Serodiagnosis of Human Fasciolosis}, year = {2011}, month = {11}, volume = {5}, url = {https://doi.org/10.1371/journal.pntd.0001376}, pages = {1-7}, abstract = {Background Human fasciolosis is a re-emerging disease worldwide and is caused by species of the genus Fasciola (F. hepatica and F. gigantica). Human fasciolosis can be diagnosed by classical coprological techniques, such as the Kato-Katz test, to reveal parasite eggs in faeces. However, although 100% specific, these methods are generally not adequate for detection of acute infections, ectopic infections, or infections with low number of parasites. In such cases immunological methods may be a good alternative and are recommended for use in major hospitals where trained personnel are available, although they are not usually implemented for individual testing. Methodology/Principal Findings We have developed a new lateral flow test (SeroFluke) for the serodiagnosis of human fasciolosis. The new test was constructed with a recombinant cathepsin L1 from F. hepatica, and uses protein A and mAb MM3 as detector reagents in the test and control lines, respectively. In comparison with an ELISA test (MM3-SERO) the SeroFluke test showed maximal specificity and sensitivity and can be used with serum or whole blood samples. Conclusions/Significance The new test can be used in major hospitals in hypoendemic countries as well as in endemic/hyperendemic regions where point-of-care testing is required.}, number = {11}, }